Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00537173 · ClinicalTrials.gov registry record
Predicting Response and Toxicity in Patients Receiving Paclitaxel and Avastin for Breast Cancer
A clinical trial, sponsored by Hoosier Cancer Research Network.
- Terminated
- Registry status
- 11
- Enrollment target
NCT00537173 is a clinical trial that was terminated before completion, run by Hoosier Cancer Research Network. The registered enrollment target is 11 participants.
The verdict
NCT00537173 was terminated before completion, sponsored by Hoosier Cancer Research Network.
- TERMINATED
- Registry status
- 11 participants
- Enrollment target
Study Summary
This trial provides a unique opportunity in that it combines genomic, proteomic and pharmacogenomic assessments in patients receiving chemotherapy for advanced breast cancer. To date no other trials have analyzed gene and protein expression at the same time points in the same patient, combined with clinical outcome. Similar to previous attempts to predict response based on expression of a single gene or protein, we expect that neither genomic or proteomic profiling alone will be sufficient to optimize therapy. Rather, we expect an iterative process that combines information gleaned from both platforms, modified to avoid toxicity based on pharmacogenomics.
Interventions
- DRUG Paclitaxel
- PROCEDURE Core Biopsy
- PROCEDURE Blood Collection
- DRUG Avastin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2007-09 |
| Est. Completion | 2009-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00537173
The ClinicalTrials.gov registry entry for NCT00537173 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoosier Cancer Research Network, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Paclitaxel is the first listed.
NCT00537173 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00537173 about?
NCT00537173 is a clinical study titled "Predicting Response and Toxicity in Patients Receiving Paclitaxel and Avastin for Breast Cancer". This trial provides a unique opportunity in that it combines genomic, proteomic and pharmacogenomic assessments in patients receiving chemotherapy for advanced breast cancer. To date no other trials have analyzed gene and protein expression at the same time points in the same patient, combined with ...
What is the current status of trial NCT00537173?
This trial is currently terminated. The enrollment target is 11 participants. The study started on 2007-09. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00537173?
The interventions under investigation include: Paclitaxel (DRUG), Core Biopsy (PROCEDURE), Blood Collection (PROCEDURE), Avastin (DRUG).
Who is sponsoring clinical trial NCT00537173?
This trial is sponsored by Hoosier Cancer Research Network, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.